MX2007012538A - Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias. - Google Patents

Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.

Info

Publication number
MX2007012538A
MX2007012538A MX2007012538A MX2007012538A MX2007012538A MX 2007012538 A MX2007012538 A MX 2007012538A MX 2007012538 A MX2007012538 A MX 2007012538A MX 2007012538 A MX2007012538 A MX 2007012538A MX 2007012538 A MX2007012538 A MX 2007012538A
Authority
MX
Mexico
Prior art keywords
lgg
medicament
prevention
manufacture
treatment
Prior art date
Application number
MX2007012538A
Other languages
English (en)
Inventor
Udo Herz
Harald Renz
Nicole Bluemer
Holger Garn
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36698734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007012538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/106,792 external-priority patent/US20060233772A1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2007012538A publication Critical patent/MX2007012538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion esta dirigida a un uso novedoso de LGG en la manufactura de un medicamento para la prevencion o tratamiento de las alergias respiratorias en un sujeto.
MX2007012538A 2005-04-15 2006-03-22 Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias. MX2007012538A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/106,792 US20060233772A1 (en) 2005-04-15 2005-04-15 Method for preventing or treating the development of respiratory allergies
US11/144,287 US7303745B2 (en) 2005-04-15 2005-06-03 Method for preventing or treating the development of respiratory allergies
PCT/US2006/010418 WO2006113035A1 (en) 2005-04-15 2006-03-22 Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies

Publications (1)

Publication Number Publication Date
MX2007012538A true MX2007012538A (es) 2007-12-10

Family

ID=36698734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012538A MX2007012538A (es) 2005-04-15 2006-03-22 Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.

Country Status (14)

Country Link
US (6) US7303745B2 (es)
EP (1) EP1868623B1 (es)
KR (2) KR101277447B1 (es)
CN (1) CN105832774B (es)
BR (1) BRPI0609077A2 (es)
CA (3) CA2881536C (es)
ES (1) ES2599156T3 (es)
MX (1) MX2007012538A (es)
MY (2) MY162223A (es)
NO (1) NO20073900L (es)
PL (1) PL1868623T3 (es)
RU (1) RU2435598C2 (es)
TW (1) TWI369210B (es)
WO (1) WO2006113035A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
CA2645472C (en) * 2006-03-10 2015-09-15 N.V. Nutricia Use of non-digestable saccharides for giving an infant the best start after birth
WO2008064489A1 (en) * 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
EP1974734A1 (en) † 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
PT2217246E (pt) * 2007-11-08 2015-02-10 Nestec Sa Utilização de oligossacáridos contendo n-acetil-lactosamina para maturação de respostas imunes em recém-nascidos
US9483911B2 (en) 2008-04-30 2016-11-01 Bally Gaming, Inc. Information distribution in gaming networks
AR072142A1 (es) 2008-06-13 2010-08-11 Nutricia Nv Nutricion para prevenir infecciones.proceso. composicion. uso.
WO2009151315A1 (en) * 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010071421A1 (en) * 2008-12-17 2010-06-24 N.V. Nutricia Probiotics for the treatment and/or prevention of pulmonary hypertension
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
JP4942831B2 (ja) * 2010-03-19 2012-05-30 株式会社キティー 抗アレルギー用組成物
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
US12018327B2 (en) 2018-03-01 2024-06-25 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
CN1200701C (zh) 1997-02-21 2005-05-11 艾博特公司 降低坏死性小肠结肠炎发生率的组合物
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CN1330542A (zh) 1998-12-15 2002-01-09 美国家用产品公司 对肠道完整性有维持和修复作用的方法与组合物
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU4905300A (en) 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
FI113741B (fi) 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
JP2003535903A (ja) 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
KR100845456B1 (ko) * 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
WO2002066037A2 (en) * 2001-02-16 2002-08-29 Eli Lilly And Company Antiviral method of use
EP1239032A1 (en) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1260227A1 (en) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
ES2192151B1 (es) * 2002-03-15 2005-02-01 Universidad Politecnica De Valencia Linea de retardo multiple basada en awg y diferentes tramos de un medio optico dispersivo.
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
US20040265291A1 (en) 2003-01-24 2004-12-30 Flora Technology Inc. Compositions and methods for restoring bacterial flora
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies

Also Published As

Publication number Publication date
BRPI0609077A2 (pt) 2010-02-17
CA2991508A1 (en) 2006-10-26
US7303745B2 (en) 2007-12-04
CA2881536C (en) 2018-02-13
RU2007137994A (ru) 2009-05-20
CA2604846C (en) 2015-05-05
RU2435598C2 (ru) 2011-12-10
TWI369210B (en) 2012-08-01
MY147175A (en) 2012-11-14
MY162223A (en) 2017-05-31
NO20073900L (no) 2008-01-10
US7867485B2 (en) 2011-01-11
CN105832774A (zh) 2016-08-10
EP1868623A1 (en) 2007-12-26
US20080118485A1 (en) 2008-05-22
EP1868623B1 (en) 2016-08-31
US20080085267A1 (en) 2008-04-10
KR20130058767A (ko) 2013-06-04
US20060233773A1 (en) 2006-10-19
KR101277447B1 (ko) 2013-06-28
US7837989B2 (en) 2010-11-23
US7923006B2 (en) 2011-04-12
PL1868623T3 (pl) 2017-03-31
TW200716145A (en) 2007-05-01
CA2881536A1 (en) 2006-10-26
US20080118484A1 (en) 2008-05-22
KR20070122479A (ko) 2007-12-31
US7867486B2 (en) 2011-01-11
CN105832774B (zh) 2020-03-06
CA2604846A1 (en) 2006-10-26
ES2599156T3 (es) 2017-01-31
WO2006113035A1 (en) 2006-10-26
US20080118483A1 (en) 2008-05-22
US20080131413A1 (en) 2008-06-05
CA2991508C (en) 2019-06-25

Similar Documents

Publication Publication Date Title
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
MXPA06013039A (es) El tratamiento de enfermedad respiratoria.
MX2008002438A (es) Cubierta de calzado desechable.
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
UA88166C2 (ru) Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
TW200700071A (en) Novel use
HK1104460A1 (en) Use for the manufacture of a medicament for treatment or prophylaxis of infectious diseases
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
HK1093729A1 (en) Substituted quinolones
GB0523961D0 (en) The treatment of ophthalmic diseases
UA104714C2 (ru) Выделенный полинуклеотид brachyspira hyodysenteriae, кодирующий полипептид, и его применение
WO2008046407A3 (de) Verwendung von deuteriumdioxid zur behandlung von hyperproliferativen erkrankungen der haut
IL194353A0 (en) Lysobactin amides
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
TW200731976A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
WO2008131859A3 (de) Verwendimg cyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
GB Transfer or rights